{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:10:07Z","timestamp":1778591407157,"version":"3.51.4"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["R01AR070116"],"award-info":[{"award-number":["R01AR070116"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["K08AR065577"],"award-info":[{"award-number":["K08AR065577"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.anai.2020.05.028","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T11:33:30Z","timestamp":1591011210000},"page":"13-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["New and emerging treatments for inflammatory itch"],"prefix":"10.1016","volume":"126","author":[{"given":"Stephen","family":"Erickson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron Ver","family":"Heul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.anai.2020.05.028_bib1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrn1950","article-title":"The neurobiology of itch","volume":"7","author":"Ikoma","year":"2006","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"10.1016\/j.anai.2020.05.028_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000319862","article-title":"Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730","volume":"221","author":"Stander","year":"2010","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.anai.2020.05.028_bib3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2340\/00015555-1159","article-title":"Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study","volume":"91","author":"Matterne","year":"2011","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"10.1016\/j.anai.2020.05.028_bib4","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archdermatol.2011.178","article-title":"The impact of pruritus on quality of life: the skin equivalent of pain","volume":"147","author":"Kini","year":"2011","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2020.05.028_bib5","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1111\/j.1468-3083.2012.04578.x","article-title":"Relationship between itch and psychological status of patients with atopic dermatitis","volume":"27","author":"Chrostowska-Plak","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.anai.2020.05.028_bib6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jid.2019.05.034","article-title":"Itch and mental health in dermatological patients across Europe: a cross-sectional study in 13 countries","volume":"140","author":"Dalgard","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2020.05.028_bib7","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/archpedi.159.8.745","article-title":"The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis","volume":"159","author":"Chamlin","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"4","key":"10.1016\/j.anai.2020.05.028_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2340\/00015555-0305","article-title":"Clinical classification of itch: a position paper of the International Forum for the Study of Itch","volume":"87","author":"Stander","year":"2007","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.anai.2020.05.028_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/bjd.16117","article-title":"British Association of Dermatologists\u2019 guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018","volume":"178","author":"Millington","year":"2018","journal-title":"Br J Dermatol"},{"issue":"17","key":"10.1016\/j.anai.2020.05.028_bib10","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMcp1208814","article-title":"Clinical practice: chronic pruritus","volume":"368","author":"Yosipovitch","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2020.05.028_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of chronic pruritus in atopic dermatitis: getting the itch out?","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7154","key":"10.1016\/j.anai.2020.05.028_bib12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/nature06029","article-title":"A\u00a0gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord","volume":"448","author":"Sun","year":"2007","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.anai.2020.05.028_bib13","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.cell.2009.11.034","article-title":"Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus","volume":"139","author":"Liu","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.anai.2020.05.028_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1744-8069-10-44","article-title":"Itch-associated peptides: RNA-seq and bioinformatic analysis of natriuretic precursor peptide B and gastrin releasing peptide in dorsal root and trigeminal ganglia, and the spinal cord","volume":"10","author":"Goswami","year":"2014","journal-title":"Mol Pain"},{"issue":"1","key":"10.1016\/j.anai.2020.05.028_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.anai.2020.05.028_bib16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A\u00a0sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"47","key":"10.1016\/j.anai.2020.05.028_bib17","doi-asserted-by":"crossref","first-page":"E7572","DOI":"10.1073\/pnas.1606608113","article-title":"IL-33\/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy","volume":"113","author":"Liu","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.anai.2020.05.028_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.anai.2020.05.028_bib19","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jaci.2014.11.001","article-title":"The 3 major types of innate and adaptive cell-mediated effector immunity","volume":"135","author":"Annunziato","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.05.028_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.anai.2020.05.028_bib21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40257-016-0213-5","article-title":"Current and emerging therapies for itch management in psoriasis","volume":"17","author":"Stull","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"10.1016\/j.anai.2020.05.028_bib22","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2020.05.028_bib23","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1124\/jpet.105.087965","article-title":"Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist","volume":"314","author":"Lim","year":"2005","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.anai.2020.05.028_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuroscience.2011.06.002","article-title":"Histamine H1, H3 and H4 receptors are involved in pruritus","volume":"190","author":"Rossbach","year":"2011","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.anai.2020.05.028_bib25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jaci.2006.08.034","article-title":"Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus","volume":"119","author":"Dunford","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2020.05.028_bib26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-3-662-44605-8_15","article-title":"Antihistamines and itch","volume":"226","author":"Thurmond","year":"2015","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"10.1016\/j.anai.2020.05.028_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1476-5381.2009.00151.x","article-title":"The role of histamine H4 receptor in immune and inflammatory disorders","volume":"157","author":"Zampeli","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.anai.2020.05.028_bib28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaci.2008.12.1110","article-title":"The histamine H4 receptor is functionally expressed on T(H)2 cells","volume":"123","author":"Gutzmer","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2020.05.028_bib29","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jaci.2013.06.023","article-title":"Histamine induces proliferation in keratinocytes from patients with atopic dermatitis through the histamine 4 receptor","volume":"132","author":"Glatzer","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2020.05.028_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/1346-8138.12726","article-title":"Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis","volume":"42","author":"Murata","year":"2015","journal-title":"J\u00a0Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2020.05.028_bib31","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jaci.2018.07.047","article-title":"Efficacy and safety of histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis","volume":"143","author":"Werfel","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2020.05.028_bib32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2020.05.028_bib33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2020.05.028_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","article-title":"Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial","volume":"174","author":"Chan","year":"2019","journal-title":"JAMA Pediatr"},{"issue":"14","key":"10.1016\/j.anai.2020.05.028_bib35","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2020.05.028_bib36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.anai.2020.05.028_bib37","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10013","key":"10.1016\/j.anai.2020.05.028_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Thaci","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.anai.2020.05.028_bib40","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.anai.2020.05.028_bib41","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti\u2013interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2020.05.028_bib42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2020.05.028_bib43","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.anai.2020.05.028_bib44","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-TSLP monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"515","key":"10.1016\/j.anai.2020.05.028_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.anai.2020.05.028_bib46","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/08998280.2018.1480246","article-title":"Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib","volume":"31","author":"Haugh","year":"2018","journal-title":"Proc Bayl Univ Med Cent"},{"issue":"3","key":"10.1016\/j.anai.2020.05.028_bib47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2020.05.028_bib48","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2020.05.028_bib49","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.anai.2020.05.028_bib50","doi-asserted-by":"crossref","unstructured":"Simpson EL, Lacour JP, Spelman L, et\u00a0al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials [e-pub ahead of print]. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.18898, accessed March 31, 2020.","DOI":"10.1111\/bjd.18898"},{"issue":"5","key":"10.1016\/j.anai.2020.05.028_bib51","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jid.2018.10.043","article-title":"A\u00a0phase 2 randomized trial of apremilast in patients with atopic dermatitis","volume":"139","author":"Simpson","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2020.05.028_bib52","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s13555-019-0305-2","article-title":"NK-1 receptor antagonists and pruritus: review of current literature","volume":"9","author":"Pojawa-Go\u0142\u0105b","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"10.1016\/j.anai.2020.05.028_bib53","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaad.2019.01.052","article-title":"Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial","volume":"80","author":"Stander","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2020.05.028_bib55","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2340\/00015555-1353","article-title":"Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"10.1016\/j.anai.2020.05.028_bib56","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/hepr.12830","article-title":"Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial","volume":"47","author":"Kumada","year":"2017","journal-title":"Hepatol Res"},{"issue":"3","key":"10.1016\/j.anai.2020.05.028_bib57","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A\u00a0phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.anai.2020.05.028_bib58","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.anai.2011.02.005","article-title":"Does the EASI score reflect itch severity?","volume":"106","author":"Shim","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"10.1016\/j.anai.2020.05.028_bib59","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.anai.2020.05.028_bib60","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jaci.2016.05.038","article-title":"Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis","volume":"138","author":"Wang","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2020.05.028_bib61","first-page":"110","article-title":"Th2 cytokines and atopic dermatitis","volume":"2","author":"Brandt","year":"2011","journal-title":"J\u00a0Clin Cell Immunol"},{"issue":"1","key":"10.1016\/j.anai.2020.05.028_bib62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ejp.767","article-title":"The pathogenesis of prurigo nodularis \u2013 \u2018super-itch\u2019 in exploration","volume":"20","author":"Zeidler","year":"2016","journal-title":"Eur J Pain"},{"issue":"2","key":"10.1016\/j.anai.2020.05.028_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13222","article-title":"Dupilumab for prurigo nodularis: case series and review of the literature","volume":"33","author":"Holm","year":"2020","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.anai.2020.05.028_bib64","first-page":"2","article-title":"Chronic pruritus responding to dupilumab\u2014a case series","volume":"6","author":"Zhai","year":"2019","journal-title":"Medicines (Basel)"},{"issue":"7","key":"10.1016\/j.anai.2020.05.028_bib65","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.anai.2020.05.028_bib66","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2020.05.028_bib67","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jaci.2008.05.047","article-title":"Correlation of IL-31 serum levels with severity of atopic dermatitis","volume":"122","author":"Raap","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2020.05.028_bib68","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3389\/fimmu.2019.01383","article-title":"Role of the pruritic cytokine IL-31 in autoimmune skin diseases","volume":"10","author":"Gibbs","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.anai.2020.05.028_bib69","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.anai.2020.05.028_bib70","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/vde.12186","article-title":"A\u00a0blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs","volume":"26","author":"Little","year":"2015","journal-title":"Vet Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2020.05.028_bib71","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2020.05.028_bib72","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjd.16014","article-title":"Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis","volume":"178","author":"Nakagawa","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2020.05.028_bib73","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jaci.2019.08.004","article-title":"Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis","volume":"144","author":"Nakagawa","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2020.05.028_bib74","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.18469","article-title":"Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study","volume":"182","author":"Worm","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2020.05.028_bib75","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2020.05.028_bib76","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2020.05.028_bib77","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/187152807780077318","article-title":"Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis","volume":"6","author":"Baumer","year":"2007","journal-title":"Inflam Allergy Drug Targets"},{"issue":"1","key":"10.1016\/j.anai.2020.05.028_bib78","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2020.05.028_bib79","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3461","article-title":"Efficacy of apremilast in patients with prurigo nodularis: a proof-of-concept study","volume":"100","author":"Todberg","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.anai.2020.05.028_bib80","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1002\/hsr2.154","article-title":"Evaluation of apremilast in chronic pruritus of unknown origin: a proof-of-concept, phase 2a, open-label, single-arm clinical trial","volume":"3","author":"Clark","year":"2020","journal-title":"Health Sci Rep"},{"issue":"5","key":"10.1016\/j.anai.2020.05.028_bib81","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaad.2018.02.030","article-title":"Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial","volume":"78","author":"Yosipovitch","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.anai.2020.05.028_bib84","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/sj.jid.5700942","article-title":"Possible roles of epidermal opioid systems in pruritus of atopic dermatitis","volume":"127","author":"Tominaga","year":"2007","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2020.05.028_bib85","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jneuroim.2008.04.021","article-title":"Bi-directional heterologous desensitization between the major HIV-1 co-receptor CXCR4 and the kappa-opioid receptor","volume":"197","author":"Finley","year":"2008","journal-title":"J\u00a0Neuroimmunol"},{"issue":"2","key":"10.1016\/j.anai.2020.05.028_bib86","first-page":"75","article-title":"Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis","volume":"28","author":"Nakao","year":"2008","journal-title":"Nihon Shinkei Seishin Yakurigaku Zasshi"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120620303914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120620303914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:23:19Z","timestamp":1778588599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120620303914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1081120620303914"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2020.05.028","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New and emerging treatments for inflammatory itch","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2020.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}